Previous reports in lung cancer patients have demonstrated that clinical benefit from tyrosine kinase inhibitors is greater in patients whose tumours harbour an EGFR mutation (Lynch et al, 2004; Tsao et al, 2005; Maemondo et al, 2010). Here, EGFR is linked to neoplasm.